GS-441524 products shown alongside a healthy kitten, reflecting care and responsibility.

II.Product Details & Core Advantages

Pharmaceutical-grade high-purity products are made from pure powder, with a purity of over 99%, meeting the strict GMP standards internationally. The injection studied in this paper eliminates adverse reactions caused by impurities, such as local irritation and systemic toxicity, and can also ensure that the antiviral efficacy of each small bottle remains consistent. This high-purity feature is particularly crucial for cats with compromised immune systems It can provide reliable efficacy and will not cause additional stress to their bodies.

Unlike oral drugs that are absorbed slowly due to the impact on the digestive process, subcutaneous injection of GS-441524 can enter the bloodstream within a few hours, making it suitable for some life-threatening cases, such as those with dangerous symptom outbreaks or rapid development of neurogenic feline infectious peritonitis. The clinical data compiled in this article can demonstrate Infected cats usually start to show an improvement in appetite and a reduction in body fluid excretion within 48 to 72 hours, which verifies the benefit of its quick onset.

The product in this article is manufactured in a 100,000-level clean room. During the production process, very strict aseptic techniques are used to prevent bacterial and fungal contamination of the product. The formula is Ph-balanced, which can minimize the irritation to the injection site during injection. The chemical stability of the product can be maintained throughout its shelf life. As long as it is stored as required, it will not affect the efficacy of the drug. In addition, its bioavailability exceeds 90%, so almost all the active ingredients can reach the target tissues, helping to achieve the best viral inhibition effect.

The flexible dosage of FIP that can be customized according to the different needs of each cat is actually related to the cat’s weight, the disease it has and the severity of the condition. Personalized dosage adjustments need to be made for each cat. Our 20mg/ml concentration preparation It enables veterinarians and cat owners to adjust the dosage between 0.4mL per kilogram and 0.8mL per kilogram based on the real-time clinical manifestations of the cat, such as the amount of infusion, whether there are neurological symptoms, and the results of blood tests. This way, there is no need to mix several small bottles of medicine.

GS-441524 can be used in all types of FIP, whether it is wet FIP with fluid accumulation in the abdomen or chest, dry FIP with organ granulosa, ocular FIP with eye inflammation, or neural FIP with affected brain and spinal cord. It can act on FCoV, regardless of where the virus is in the cat’s body. In this way, there is no need to prepare several different kinds of medicine, and it will be much easier to take care of those complex cases.

20mg/mL GS-441524 injection supplied in 10mL vial.

III.Comprehensive Product Instructions

1. Usage & Administration

1.1 Route: Subcutaneous injection (avoid muscles/veins).

1.2 Sites: Preferred areas include loose skin behind the scapulae or lower back sides; rotate sites daily to prevent irritation, induration or hair loss.

1.3 Preparation: Disinfect the site with 75% alcohol; draw the required volume into a sterile syringe (25G/27G needle recommended for minimal discomfort); pinch skin to form a tent, insert the needle at a 45° angle and inject slowly.

1.4 Frequency: Once every 24 hours to maintain consistent blood concentrations.

2. Storage Requirements

2.1 Unopened Vials: Store in a refrigerator (2–4℃), away from sunlight, heat and freezing temperatures to avoid formulation damage.

2.2 Opened Vials: Seal with the original rubber stopper, store at 2–4℃ and use within 7 days; discard unused solution to prevent contamination.

3. Treatment Duration

3.1 Minimum 45 days: For mild wet FIP with rapid symptom resolution (e.g., full effusion absorption within 2 weeks).

3.2 Standard 84 days (12 weeks): For dry, ocular or neurological FIP, which carry higher recurrence risks due to persistent viral reservoirs in organs.

3.3 Discontinuation Criteria: Treatment can end only when all four conditions are met: (1) Normal CBC and biochemistry panel (including globulin levels); (2) Lymphocyte percentage ≥0.7; (3) No clinical symptoms (no effusion, normal appetite/activity, clear eyes, no neurological signs); (4) Optional negative FCoV RNA test for added certainty.

IV.Frequently Asked Questions (FAQs)

Q1: What’s the difference between GS-441524 injection and oral tablets?